Shopping Cart
- Remove All
Your shopping cart is currently empty
Ravulizumab (ALXN1210) is a humanized monoclonal antibody that specifically binds to human complement protein C5 with high affinity, targeting complement factor 5 to block complement activation. It can be used for the prevention and treatment of paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, and myasthenia gravis.
| Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 1 mg | $247 | In Stock | |
| 5 mg | $619 | In Stock | |
| 10 mg | $993 | In Stock | |
| 25 mg | $1,470 | In Stock | |
| 50 mg | $1,980 | In Stock | |
| 100 mg | $2,680 | In Stock |
| Description | Ravulizumab (ALXN1210) is a humanized monoclonal antibody that specifically binds to human complement protein C5 with high affinity, targeting complement factor 5 to block complement activation. It can be used for the prevention and treatment of paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, and myasthenia gravis. |
| In vitro | Binding to C5 with high affinity, Ravulizumab inhibits the formation of C5a and C5b, thereby preventing immune activation and hemolysis [1]. |
| Synonyms | ALXN1210 |
| Molecular Weight | 145.80 kDa |
| Cas No. | 1803171-55-2 |
| Color | Transparent |
| Appearance | Liquid |
| Storage | store at low temperature | -20°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.